MediWound Stock Earnings Estimates Reduced by HC Wainwright

MediWound Ltd. (NASDAQ:MDWD – Free Report) – HC Wainwright lowered their FY2030 EPS estimates for shares of MediWound in a report issued on Friday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings per share of $1.95 for the year, down from their previous forecast of $2.25. The consensus estimate for MediWound’s current full-year earnings is ($2.37) per share.

Other research analysts have also issued research reports about the company. Oppenheimer reissued an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a research note on Friday, August 14th. Alliance Global Partners reiterated a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Weiss Ratings downgraded MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. TD Cowen reiterated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Finally, Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 26th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

View Our Latest Stock Report on MediWound

MediWound Trading Up 5.0%

Shares of MDWD opened at $13.55 on Monday. The stock has a fifty day moving average of $13.21 and a two-hundred day moving average of $15.03. MediWound has a fifty-two week low of $11.80 and a fifty-two week high of $19.70.

MediWound (NASDAQ:MDWD – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. MediWound had a negative net margin of 234.98% and a negative return on equity of 58.44%. The business had revenue of $3.57 million during the quarter, compared to analyst estimates of $6.73 million.

Hedge Funds Weigh In On MediWound

An institutional investor recently bought a new position in MediWound stock. Marshall Wace LLP purchased a new stake in MediWound Ltd. (NASDAQ:MDWD – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 15,026 shares of the biopharmaceutical company’s stock, valued at approximately $207,000. Marshall Wace LLP owned approximately 0.12% of MediWound at the end of the most recent quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

Insider Transactions at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.

MediWound Company Profile

(Get Free Report)

MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.

Recommended Stories

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.